Pfizer India (PFIZER) Q3 25/26 earnings summary

Executive summary

• Unaudited financial results for the quarter and nine months ended December 31, 2025, were approved by the Board on February 9, 2026.

• Financials prepared in accordance with Ind AS and reviewed by statutory auditors with no modifications.

Financial highlights

• Revenue from operations for Q3 FY26 was ₹642.34 crore, compared to ₹645.03 crore in Q3 FY25 and ₹537.99 crore in Q2 FY26.

• Net profit for Q3 FY26 was ₹189.02 crore, up from ₹141.84 crore in Q3 FY25 and ₹127.60 crore in Q2 FY26.

• Total income for the nine months ended December 31, 2025, was ₹1,890.42 crore, compared to ₹1,689.44 crore for the same period last year.

• Earnings per share (EPS) for Q3 FY26 was ₹41.32, up from ₹31.01 in Q3 FY25.

Outlook and guidance

• The company continues to monitor the impact of the new Labour Codes and will account for any further changes as per applicable standards.